Glioblastoma
What's New
Last Posted: Nov 03, 2020
- Evaluation of an Assay for MGMT Gene Promoter Methylation in Glioblastoma Samples.
Filipits Martin et al. Anticancer research 2020 Nov 40(11) 6229-6236 - Utility of methylthioadenosine phosphorylase immunohistochemical deficiency as a surrogate for CDKN2A homozygous deletion in the assessment of adult-type infiltrating astrocytoma.
Satomi Kaishi et al. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2020 Oct - Novel Molecular Markers in Glioblastoma-Benefits of Liquid Biopsy.
Birkó Zsuzsanna et al. International journal of molecular sciences 2020 Oct 21(20) - Incorporating genomic signatures into surgical and medical decision-making for elderly glioblastoma patients.
Ene Chibawanye I et al. Neurosurgical focus 2020 Oct 49(4) E11 - Development of a Nomogram With Alternative Splicing Signatures for Predicting the Prognosis of Glioblastoma: A Study Based on Large-Scale Sequencing Data.
Wang Zihao et al. Frontiers in oncology 2020 101257 - Diffusion Histology Imaging Combining Diffusion Basis Spectrum Imaging (DBSI) and Machine Learning Improves Detection and Classification of Glioblastoma Pathology.
Ye Zezhong et al. Clinical cancer research : an official journal of the American Association for Cancer Research 2020 Jul - Targeted next-generation sequencing of adult gliomas for retrospective prognostic evaluation and up-front diagnostics.
Petersen Jeanette K et al. Neuropathology and applied neurobiology 2020 Jul - A fully automated artificial intelligence method for non-invasive, imaging-based identification of genetic alterations in glioblastomas.
Calabrese Evan et al. Scientific reports 2020 Jul 10(1) 11852 - A Molecular Signature associated with prolonged survival in Glioblastoma patients treated with Regorafenib.
Santangelo Alessandra et al. Neuro-oncology 2020 Jul - Integrated pharmaco-proteogenomics defines two subgroups in isocitrate dehydrogenase wild-type glioblastoma with prognostic and therapeutic opportunities.
Oh Sejin et al. Nature communications 2020 Jul 11(1) 3288 - Convolutional neural networks for brain tumour segmentation.
Bhandari Abhishta et al. Insights into imaging 2020 Jun 11(1) 77 - Implementation of model explainability for a basic brain tumor detection using convolutional neural networks on MRI slices.
Windisch Paul et al. Neuroradiology 2020 Jun - Assessment of genetic and non-genetic risk factors for venous thromboembolism in glioblastoma - The predictive significance of B blood group.
Heenkenda Menikae K et al. Thrombosis research 2019 Nov 183136-142 - Integrating Genomic Data with Transcriptomic Data for Improved Survival Prediction for Adult Diffuse Glioma.
Yang Qi et al. Journal of Cancer 2020 11(13) 3794-3802 - Integrated Analysis to Evaluate the Prognostic Value of Signature mRNAs in Glioblastoma Multiforme.
Yang Ji'an et al. Frontiers in genetics 2020 11253
About Rare Diseases PHGKB
Rare Disease PHGKB is an online, continuously updated, searchable database of published scientific literature, CDC and NIH resources, and other information that address the public health impact and translation of genomic discoveries into improved health outcomes related to rare diseases...more
Content Summary
- NIH Information (3)
- COVID-19 (4)
- CDC Publications (1)
- Human Genome Epidemiologic Studies (328)
- GWAS Studies (7)
- Human Genomics Translation/Implementation Studies (64)
- Genomic Tests Evidence Synthesis (4)
- Genomic Tests Guidelines (1)
- Non-Genomics Precision Health (13)
- Pathogen Advanced Molecular Detection (1)
- State Public Health Genomics Programs (1)
- Reviews/Commentaries (29)
Selected Rare Diseases
- Alpha-1 Antitrypsin Deficiency
- Amyotrophic Lateral Sclerosis
- Brugada Syndrome
- Cerebral Palsy
- Cystic Fibrosis
- Duchenne Muscular Dystrophy
- Eclampsia
- Erythema Multiforme
- Familial Mediterranean Fever
- Fragile X Syndrome
- Gaucher Disease
- Glomerulonephritis
- Graves Disease
- Hemophilia
- Huntington Disease
- Microcephaly
- Myasthenia Gravis
- Phenylketonuria
- Retinitis Pigmentosa
- Severe Combined Immunodeficiency
Disclaimer: Articles listed in the Public Health Knowledge Base are selected by the CDC Office of Public Health Genomics to provide current awareness of the literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the update, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.
- Page last reviewed:Oct 1, 2020
- Page last updated:Dec 29, 2020
- Content source: